NIH Funding Opportunities (Notices, PA, RFA)

Weekly Funding Opportunities and Policy Notices from the National Institutes of Health.
Updated: 2 hours 35 min ago
Fertility Status as a Marker for Overall Health (R21 Clinical Trial Not Allowed)
Funding Opportunity PAR-20-282 from the NIH Guide for Grants and Contracts. T?he purpose of this funding opportunity announcement (FOA) is to support exploratory/developmental research that explores the premise that fertility status can be a marker for overall health. Chronic conditions such as cancer, diabetes, and obesity can impair fertility, however, less is known about the extent to which fertility status can impact or act as a marker for overall health. Data suggest that infertility is not necessarily a unique disease of the reproductive axis but is often physiologically or genetically linked with other diseases and conditions. Recent epidemiologic studies demonstrate links between fertility status in both males and females and various somatic diseases and disorders. Taken together, these data strongly suggest that fertility status can be a window into overall health. Advancing this premise will require substantive involvement of experts in reproductive health/fertility along with expert in another non-reproductive specialty appropriate to the area of overall health being investigated, for example, experts in other fields such as epidemiology, or the somatic disease in question,. This FOA focuses on studies evaluating fertility as a marker for overall health, and therefore applications that look at the effects of a disease or disorder on fertility are outside of the scope of this program. Recruitment of new cohorts will not be supported by this FOA.
Categories: Job Watch, Literature Watch
Limited Competition for the Continuation of the Look AHEAD (Action for Health in Diabetes) Study (U01 Clinical Trial Not Allowed)
Funding Opportunity RFA-AG-21-028 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is a limited competition FOA inviting cooperative agreement (U01) applications from investigators currently participating in the Look AHEAD (Action for Health in Diabetes) Consortium. The purpose of this limited competition will be to allow an additional 5-year follow-up period of all currently enrolled participants. The goals of the Action for Health in Diabetes Extension (Look AHEAD-E) study are to examine the long-term effects of an intensive lifestyle intervention designed to produce weight loss on health, function, and healthcare utilization.
Categories: Job Watch, Literature Watch
Notice of Change to Award Information in PAR-19-242, Paul Calabresi Career Development for Clinical Oncology (K12 Clinical Trial Optional)
Notice NOT-CA-20-088 from the NIH Guide for Grants and Contracts
Categories: Job Watch, Literature Watch
Notice of Change to the Application Instructions for the Candidate Eligibility Statement in PAR-19-343 "Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Postdoctoral Career Transition Award to Promote Diversity (K99/R00)"
Notice NOT-GM-20-038 from the NIH Guide for Grants and Contracts
Categories: Job Watch, Literature Watch
Notice of Pre-Application Webinar for Developmental Genotype-Tissue Expression Project (dGTEx)
Notice NOT-HG-20-052 from the NIH Guide for Grants and Contracts
Categories: Job Watch, Literature Watch
Request for Information (RFI) on Flexibilities for Conducting Semiannual Animal Facility Inspections
Notice NOT-OD-20-145 from the NIH Guide for Grants and Contracts
Categories: Job Watch, Literature Watch
AHRQ Grant Recipient use of the eRA Commons to Submit First-Time No-Cost Extension (NCE) Notifications for Grant Awards that are under Expanded Authorities
Notice NOT-HS-20-012 from the NIH Guide for Grants and Contracts
Categories: Job Watch, Literature Watch
Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed)
Funding Opportunity PAR-20-277 from the NIH Guide for Grants and Contracts. Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) along with the National Human Genome Research Institute (NHGRI) and National Institute of Dental and Craniofacial Research (NIDCR) encourages submission of applications proposing to conduct secondary data analysis and integration of existing datasets and database resources, with the ultimate aim to elucidate the genetic architecture of cancer risk and related outcomes (e.g., risk prediction or reduction, survival, or response to treatment, etc.). The goal of this initiative is to address key scientific questions relevant to cancer genomic and epidemiology by supporting the analysis of existing genetic or genomic datasets, in combination with other omics and environmental, clinical, behavioral, lifestyle, and molecular profiles data. Applicants are encouraged to leverage existing genetic data and perform innovative analyses of the existing data. Applications may include new research aims that are being addressed with existing data, new or advanced methods of analyses, or novel combinations and integration of datasets that allow the exploration of important scientific questions in genomic and epidemiology cancer research.
Categories: Job Watch, Literature Watch
Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed)
Funding Opportunity PAR-20-276 from the NIH Guide for Grants and Contracts. Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) along with the National Human Genome Research Institute (NHGRI) and National Institute of Dental and Craniofacial Research (NIDCR) encourages submission of applications proposing to conduct secondary data analysis and integration of existing datasets and database resources, with the ultimate aim to elucidate the genetic architecture of cancer risk and related outcomes (e.g., risk prediction or reduction, survival, or response to treatment, etc.). The goal of this initiative is to address key scientific questions relevant to cancer genomic and epidemiology by supporting the analysis of existing genetic or genomic datasets, in combination with other omics and environmental, clinical, behavioral, lifestyle, and molecular profiles data. Applicants are encouraged to leverage existing genetic data and perform innovative analyses of the existing data. Applications may include new research aims that are being addressed with existing data, new or advanced methods of analyses, or novel combinations and integration of datasets that allow the exploration of important scientific questions in genomic and epidemiology cancer research.
Categories: Job Watch, Literature Watch
Notice to Reduce the Number of Research Projects Required in PAR-19-313 "Centers of Biomedical Research Excellence (COBRE) Phase 1 (P20 Clinical Trial Optional)"
Notice NOT-GM-20-042 from the NIH Guide for Grants and Contracts
Categories: Job Watch, Literature Watch
Notice of Correction to PAR-20-221, "NIDA Avant-Garde Award Program for HIV/AIDS and Substance Use Disorder Research (DP1, Clinical Trial Optional)"
Notice NOT-DA-20-066 from the NIH Guide for Grants and Contracts
Categories: Job Watch, Literature Watch
Notice of Change to Key Dates and Post Submission Materials Guideline in RFA-CA-20-033, "SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies Toward Commercialization (R44 Clinical Trial Optional)"
Notice NOT-CA-20-087 from the NIH Guide for Grants and Contracts
Categories: Job Watch, Literature Watch
Notice of Special Interest: Fundamental and Translational Research on Decision Making in Aging and/or Alzheimers Disease and Alzheimers Disease Related Dementias (AD/ADRD)
Notice NOT-AG-20-039 from the NIH Guide for Grants and Contracts
Categories: Job Watch, Literature Watch
Notice to Reduce the Number of Research Projects Required in PAR-19-312 "Limited Competition: Renewal of Centers of Biomedical Research Excellence (COBRE) (Phase 2) (P20 Clinical Trial Optional)"
Notice NOT-GM-20-043 from the NIH Guide for Grants and Contracts
Categories: Job Watch, Literature Watch
Request for Proposal (RFP) Notice: NHLBI Progenitor Cell Translational Consortium (PCTC) - Scientific Services to Conduct In-depth Cell Characterization for the NIH Regenerative Medicine Innovation Project 2020
Notice NOT-HL-20-798 from the NIH Guide for Grants and Contracts
Categories: Job Watch, Literature Watch
Notice of Change: Extension to end date for NOT-OD-20-130 RFI: Enhancing Rigor, Transparency, and Translatability to Improve Biomedical Research Involving Animal Models
Notice NOT-OD-20-142 from the NIH Guide for Grants and Contracts
Categories: Job Watch, Literature Watch
NIEHS Research Intensive Short Courses and Educational Opportunities (NIEHS RISE) (R25 Clinical Trial Not Allowed)
Funding Opportunity RFA-ES-20-015 from the NIH Guide for Grants and Contracts. The intent of this FOA is to encourage applications to develop and conduct short-term research education activities with the goal of providing training to improve knowledge and skills needed to conduct environmental health research. Short courses submitted under this FOA are expected to include relevant intensive hands-on training in environmental health science topics. In addition to in-person instruction, courses that incorporate innovative or novel education models, such as project-based learning or virtual instruction, are encouraged.
Categories: Job Watch, Literature Watch
Assay development and screening for discovery of chemical probes, drugs or immunomodulators (R01 Clinical Trial Not Allowed)
Funding Opportunity PAR-20-271 from the NIH Guide for Grants and Contracts. The goal of this FOA is identification of small molecules that function to elucidate the biology of disease as chemical probes or function as agonists or antagonists of disease target(s) for therapy or immunotherapy. The FOA is intended to support discovery research for the identification of validated hits relevant to health-related outcomes of participating NIH Institutes. Stages of discovery research covered by this FOA include: 1) assay development for specific biological targets and disease mechanisms relevant to the mission of participating NIH Institutes with the intent to screen for small molecule compounds that show potential as probes for use in advancing knowledge about the known targets, identifying new targets, or as pre-therapeutic leads; 2) screen implementation high throughput target-focused approaches or moderate throughput phenotypic- and fragment-based approaches to identify initial screening hits; 3) hit validation, including implementation of secondary assays that are orthogonal to the primary assay, advanced cheminformatics analysis and initial medicinal chemistry inspection to prioritize the hit set, and follow-up assays to characterize mode and mechanism of action of the validated hits; 4) hit-to-lead optimization, including SAR to optimize target engagement, selectivity and to minimize chemical liabilities, ADME, PK and PD studies, and, if appropriate, in vivo modeling to test efficacy or biological effects.
Categories: Job Watch, Literature Watch
NIDA Core "Center of Excellence" Grant Program (P30 Clinical Trial Optional)
Funding Opportunity PAR-20-267 from the NIH Guide for Grants and Contracts. NIDA Core Center of Excellence Grants (P30) are intended to bring together investigators currently funded by NIH or other Federal or non-Federal sources, to enhance the effectiveness of existing research and also to extend the focus of research to drug abuse and addiction. It is expected that a Center will transform knowledge in the sciences it is studying. Incremental work should not be the focus of Center activities; rather, new and creative directions are encouraged. An application should integrate and promote research in existing funded projects, to achieve new and creative directions. It is expected that individual core activities reflect a relationship to the integrating theme of the Center and the Center is expected to provide research opportunities and experiences to new investigators , and share findings, data and their resources, consistent with achieving the goals of the program.
Categories: Job Watch, Literature Watch
Integrative Research to Understand the Impact of Sex Differences on the Molecular Determinants of AD Risk and Responsiveness to Treatment (R01 Clinical Trial Optional)
Funding Opportunity PAR-20-269 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications that apply a cross-disciplinary and team science approach to gain comprehensive mechanistic understanding of the impact of sex differences on the trajectories of brain aging, phenotypes, and risk of Alzheimer's Disease (AD) and AD-related dementia (ADRD), and on precision medicine for treatment and prevention of AD/ADRD, including the responsiveness to pharmacologic and non-pharmacologic interventions.
Categories: Job Watch, Literature Watch